Avacopan Patent Expiration
Avacopan is Used for treating severe active ANCA-associated vasculitis in adult patients in combination with standard therapy. It was first introduced by Chemocentryx Inc
Avacopan Patents
Given below is the list of patents protecting Avacopan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tavneos | US11603356 | Amorphous form of a complement component C5a receptor | May 29, 2041 | Chemocentryx |
| Tavneos | US11951214 | Capsule formulations | Nov 27, 2039 | Chemocentryx |
| Tavneos | US8445515 | C5aR antagonists | Feb 03, 2031 | Chemocentryx |
| Tavneos | US8906938 | C5aR antagonists | Dec 21, 2029 | Chemocentryx |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Avacopan's patents.
Latest Legal Activities on Avacopan's Patents
Given below is the list recent legal activities going on the following patents of Avacopan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 16 Apr, 2024 | US11951214 |
| Change in Power of Attorney (May Include Associate POA) Critical | 16 Apr, 2024 | US11951214 |
| Change in Power of Attorney (May Include Associate POA) Critical | 12 Apr, 2024 | US8445515 |
| Change in Power of Attorney (May Include Associate POA) Critical | 12 Apr, 2024 | US8906938 |
| Email Notification Critical | 12 Apr, 2024 | US8445515 |
| Email Notification Critical | 12 Apr, 2024 | US8906938 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951214 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951214 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951214 |
| Email Notification Critical | 09 Apr, 2024 | US11951214 |
Avacopan's Family Patents
